HomeCompareBPMUF vs SBUX

BPMUF vs SBUX: Dividend Comparison 2026

BPMUF yields 2.82% · SBUX yields 2.84%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 SBUX wins by $143.1K in total portfolio value
10 years
BPMUF
BPMUF
● Live price
2.82%
Share price
$71.00
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$23.9K
Annual income
$337.79
Full BPMUF calculator →
SBUX
SBUX
● Live price
2.84%
Share price
$86.72
Annual div
$2.46
5Y div CAGR
48.3%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$167.0K
Annual income
$71,136.45
Full SBUX calculator →

Portfolio growth — BPMUF vs SBUX

📍 SBUX pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodBPMUFSBUX
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, BPMUF + SBUX cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
BPMUF pays
SBUX pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

BPMUF
Annual income on $10K today (after 15% tax)
$239.44/yr
After 10yr DRIP, annual income (after tax)
$287.12/yr
SBUX
Annual income on $10K today (after 15% tax)
$241.12/yr
After 10yr DRIP, annual income (after tax)
$60,465.98/yr
At 15% tax rate, SBUX beats the other by $60,178.86/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of BPMUF + SBUX for your $10,000?

BPMUF: 50%SBUX: 50%
100% SBUX50/50100% BPMUF
Portfolio after 10yr
$95.5K
Annual income
$35,737.13/yr
Blended yield
37.43%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on SBUX right now

BPMUF
Analyst Ratings
1
Buy
Consensus: Buy
Altman Z
2.1
Piotroski
8/9
SBUX
Analyst Ratings
28
Buy
27
Hold
3
Sell
Consensus: Buy
Price Target
$104.00
+19.9% upside vs current
Range: $90.00 — $120.00
Altman Z
2.6
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

BPMUF buys
0
SBUX buys
0
No recent congressional trades found for BPMUF or SBUX in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricBPMUFSBUX
Forward yield2.82%2.84%
Annual dividend / share$2.00$2.46
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%48.3%
Portfolio after 10y$23.9K$167.0K
Annual income after 10y$337.79$71,136.45
Total dividends collected$3.1K$136.4K
Payment frequencyquarterlyquarterly
SectorStockConsumer Discretionary
Analyst consensusBuyBuy

Year-by-year: BPMUF vs SBUX ($10,000, DRIP)

YearBPMUF PortfolioBPMUF Income/yrSBUX PortfolioSBUX Income/yrGap
1← crossover$10,982$281.69$11,121$420.68$139.00SBUX
2$12,040$289.11$12,548$648.40$508.00SBUX
3$13,178$296.22$14,440$1,013.98$1.3KSBUX
4$14,404$303.03$17,068$1,617.30$2.7KSBUX
5$15,722$309.54$20,912$2,649.52$5.2KSBUX
6$17,138$315.76$26,875$4,499.29$9.7KSBUX
7$18,659$321.69$36,771$8,014.12$18.1KSBUX
8$20,293$327.33$54,542$15,197.11$34.2KSBUX
9$22,046$332.70$89,602$31,242.49$67.6KSBUX
10$23,927$337.79$167,011$71,136.45$143.1KSBUX

BPMUF vs SBUX: Complete Analysis 2026

BPMUFStock

Basilea Pharmaceutica AG, a commercial stage biopharmaceutical company, focuses on the development of products that address the medical needs in the therapeutic areas of oncology and anti-infectives. It offers Cresemba, an intravenous and oral azole antifungal drug for the treatment of invasive aspergillosis and mucormycosis in the United States, and the European Union, as well as in Phase III clinical trials for invasive fungal infections in Japan. The company also provides Zevtera, an antibiotic for the treatment of community and hospital-acquired pneumonia, as well as in Phase III clinical trials for the treatment of acute bacterial skin and skin structure infections, and Staphylococcus aureus bacteremia. In addition, it engages in developing Derazantinib, a small molecule inhibitor, which is in phase 2 clinical trial for bile duct cancer, as well as in phase ½ clinical trial for bladder and stomach cancer; and Lisavanbulin, a tumor checkpoint controller drug. Basilea Pharmaceutica AG was founded in 2000 and is headquartered in Basel, Switzerland.

Full BPMUF Calculator →

SBUXConsumer Discretionary

Starbucks Corporation, together with its subsidiaries, operates as a roaster, marketer, and retailer of specialty coffee worldwide. The company operates through three segments: North America, International, and Channel Development. Its stores offer coffee and tea beverages, roasted whole beans and ground coffees, single serve products, and ready-to-drink beverages; and various food products, such as pastries, breakfast sandwiches, and lunch items. The company also licenses its trademarks through licensed stores, and grocery and foodservice accounts. The company offers its products under the Starbucks, Teavana, Seattle's Best Coffee, Evolution Fresh, Ethos, Starbucks Reserve, and Princi brands. As of October 3, 2021, it operated 16,826 company-operated and licensed stores in North America; and 17,007 company-operated and licensed stores internationally. The company was founded in 1971 and is based in Seattle, Washington.

Full SBUX Calculator →
📬

Get this BPMUF vs SBUX comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

BPMUF vs SCHDBPMUF vs JEPIBPMUF vs OBPMUF vs KOBPMUF vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.